(FILES) In this file handout illustration image obtained February 27, 2020 courtesy of the National Institutes of Health shows a transmission electron microscopic image that shows SARS-CoV-2—also known as 2019-nCoV, the virus that causes COVID-19, isolated from a patient in the US, as the Virus particles are shown emerging from the surface of cells cultured in the lab- the spikes on the outer edge of the virus particles give coronaviruses their name, crown-like. - The prestigious journal Science on February 18, 2021 published an editorial calling for a global effort to develop a universal coronavirus vaccine that would remain effective against other members of the same virus family that might cross over to humans. Wayne Koff, head of the Human Vaccines Project, and Seth Berkley, who leads the global vaccine alliance Gavi, said that although the Covid-19 pandemic was far from over, humanity now possessed the tools to end it and was undertaking the most rapid immunization campaign in history. (Photo by Handout / National Institutes of Health / AFP) / RESTRICTED TO EDITORIAL USE - MANDATORY CREDIT "AFP PHOTO /NATIONAL INSTITUTES OF HEALTH/NIAID-RML/HANDOUT " - NO MARKETING - NO ADVERTISING CAMPAIGNS - DISTRIBUTED AS A SERVICE TO CLIENTS | Photo Credit: HANDOUT
Researchers at the University of Maryland School of Medicine (UMSOM) found the most toxic protein produced by SARS-CoV-2 and then used an FDA-approved cancer drug to mitigate the lethal effects.
In their experiments in fruit flies and human cell lines, the team found the cell process that the virus hijacks. They discovered new potential candidate drugs that could be tested for treating severe Covid-19 disease patients.
Their findings were published in the journals Cell & Bioscience, a Springer Nature journal.
“Our work suggests there is a way to prevent SARS-COV-2 from injuring the body’s tissues and doing extensive damage,” says senior author of the study Zhe “Zion” Han, PhD, Associate Professor of Medicine and Director of the Center for Precision Disease Modeling at UMSOM.
He noted that the most effective drug against Covid-19, remdesivir, only prevents the virus from making more copies of itself. However, it does not protect already infected cells from damage caused by the viral proteins.
The authors of the study discovered that a viral protein, known as Orf6, was the most toxic killing about half of the human cells. Two other proteins (Nsp6 and Orf7a) also proved toxic, killing about 30-40 per cent of the human cells.
Dr. Han’s team found that the virus’s toxic Orf6 protein sticks to multiple human proteins that have the job of moving materials out of the cell’s nucleus--the place in the cell that holds the genome, or the instructions for life.
They then discovered that one of these human moving proteins, targeted by the virus, gets blocked by the cancer drug selinexor.
The researchers then tested selinexor on human cells and fruit flies making the toxic viral protein to see if the drug could help reverse the damage. Selinexor, like many cancer drugs, is itself toxic.
However, the drug improved human cell survival by about 12 per cent. Selinexor prevented early death in about 15 per cent of the flies making the toxic viral protein. Selinexor is FDA-approved to treat certain blood cancers.
“More than 1,000 FDA-approved drugs are in clinical trials to test as treatments for Covid-19, and luckily a trial testing selinexor, the drug used in our study, is being performed already,” said Dr. Han.
“If this trial proves to be successful, our data will have demonstrated the underlying mechanism for why the drug works,” he added.
Published on March 27, 2021
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.